Aldeyra Therapeutics, Inc. — All Filings
621 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-K/A
10-Q
144
3
4
4/A
424B1
424B4
424B5
8-A12B
8-A12B/A
8-K
8-K/A
ARS
CERTNAS
CORRESP
CT ORDER
D
DEF 14A
DEFA14A
DRS
DRS/A
EFFECT
FWP
POS AM
REGDEX
S-1
S-1/A
S-3
S-8
S-8 POS
SC 13G
SC 13G/A
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| SCHEDULE 13G/A | — | 0000102909-26-000589 | Mar 26, 2026 | — |
| 4 | 4 | 0001193125-26-117675 | Mar 20, 2026 | Mar 19, 2026 |
| 4 | 4 | 0001193125-26-116247 | Mar 19, 2026 | Mar 18, 2026 |
| 8-K | 8-K | 0001193125-26-109511 | Mar 17, 2026 | — |
| S-8 | S-8 | 0001193125-26-083135 | Feb 27, 2026 | — |
| 10-K | 10-K | 0001193125-26-083012 | Feb 27, 2026 | Dec 31, 2025 |
| SCHEDULE 13G/A | — | 0001193125-26-054525 | Feb 17, 2026 | — |
| 8-K | 8-K | 0001193125-25-338394 | Dec 31, 2025 | Dec 23, 2025 |
| 8-K | 8-K | 0001193125-25-319638 | Dec 16, 2025 | Dec 15, 2025 |
| SCHEDULE 13G/A | — | 0001193125-25-282830 | Nov 14, 2025 | — |
| 8-K | 8-K | 0001193125-25-278804 | Nov 13, 2025 | — |
| 10-Q | 10-Q | 0001193125-25-266989 | Nov 5, 2025 | Sep 30, 2025 |
| 8-K | 8-K | 0001193125-25-252200 | Oct 28, 2025 | — |
| 8-K | 8-K | 0000950170-25-109932 | Aug 19, 2025 | — |
| 4 | 4 | 0000950170-25-109391 | Aug 15, 2025 | Aug 13, 2025 |
| SCHEDULE 13G/A | — | 0000950170-25-108920 | Aug 14, 2025 | — |
| 4 | 4 | 0000950170-25-108210 | Aug 13, 2025 | Aug 11, 2025 |
| 144 | — | 0001836354-25-000003 | Aug 12, 2025 | — |
| 10-Q | 10-Q | 0000950170-25-104971 | Aug 7, 2025 | Jun 30, 2025 |
| 8-K | CURRENT REPORT | 0001213900-25-064869 | Jul 17, 2025 | — |
| 8-K | CURRENT REPORT | 0001213900-25-058035 | Jun 26, 2025 | — |
| 8-K | FORM 8-K | 0001213900-25-054949 | Jun 17, 2025 | — |
| 4 | 4 | 0000950170-25-085489 | Jun 12, 2025 | Jun 10, 2025 |
| 4 | 4 | 0000950170-25-085475 | Jun 12, 2025 | Jun 10, 2025 |
| 4 | 4 | 0000950170-25-085454 | Jun 12, 2025 | Jun 10, 2025 |
| 4 | 4 | 0000950170-25-085445 | Jun 12, 2025 | Jun 10, 2025 |
| 4 | 4 | 0000950170-25-085441 | Jun 12, 2025 | Jun 10, 2025 |
| 4 | 4 | 0000950170-25-085419 | Jun 12, 2025 | Jun 10, 2025 |
| 8-K | 8-K | 0000950170-25-084820 | Jun 11, 2025 | Jun 10, 2025 |
| 10-Q | 10-Q | 0000950170-25-071602 | May 14, 2025 | Mar 31, 2025 |
| 8-K | 8-K | 0001193125-25-113275 | May 6, 2025 | May 5, 2025 |
| ARS | ARS | 0001193125-25-096939 | Apr 25, 2025 | Dec 31, 2024 |
| DEFA14A | DEFA14A | 0001193125-25-096925 | Apr 25, 2025 | — |
| DEF 14A | DEF 14A | 0001193125-25-096899 | Apr 25, 2025 | Jun 10, 2025 |
| 4 | 4 | 0000950170-25-055900 | Apr 18, 2025 | Apr 17, 2025 |
| 3 | 3 | 0000950170-25-055877 | Apr 18, 2025 | Apr 17, 2025 |
| 8-K | CURRENT REPORT | 0001213900-25-032947 | Apr 17, 2025 | — |
| SCHEDULE 13G/A | — | 0000950170-25-051722 | Apr 7, 2025 | — |
| 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 0001062993-25-007163 | Apr 7, 2025 | Apr 3, 2025 |
| 8-K | 8-K | 0001193125-25-072424 | Apr 3, 2025 | — |
| 10-K/A | 10-K/A | 0000950170-25-046946 | Mar 28, 2025 | Dec 31, 2024 |
| 4 | 4 | 0000950170-25-034674 | Mar 6, 2025 | Mar 4, 2025 |
| 4 | 4 | 0000950170-25-034648 | Mar 6, 2025 | Mar 4, 2025 |
| S-8 | S-8 | 0001193125-25-042772 | Feb 28, 2025 | — |
| 10-K | 10-K | 0000950170-25-030102 | Feb 28, 2025 | Dec 31, 2024 |
| 8-K | CURRENT REPORT | 0001213900-24-099333 | Nov 18, 2024 | Nov 15, 2024 |
| SC 13G/A | SC 13G/A | 0001193125-24-258735 | Nov 14, 2024 | — |
| 10-Q | 10-Q | 0000950170-24-123248 | Nov 7, 2024 | Sep 30, 2024 |
| 4 | 4 | 0000950170-24-116048 | Oct 21, 2024 | May 3, 2021 |
| 8-K | CURRENT REPORT | 0001213900-24-084844 | Oct 3, 2024 | — |